Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/ipab-dismisses-bayer039s-stay-plea-in-nexavar-case-17182/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/ipab-dismisses-bayer039s-stay-plea-in-nexavar-case-17182/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/ipab-dismisses-bayer039s-stay-plea-in-nexavar-case-17182/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/ipab-dismisses-bayer039s-stay-plea-in-nexavar-case-17182/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f044c1b453e-trace').style.display = (document.getElementById('cakeErr67f044c1b453e-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f044c1b453e-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f044c1b453e-code').style.display = (document.getElementById('cakeErr67f044c1b453e-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f044c1b453e-context').style.display = (document.getElementById('cakeErr67f044c1b453e-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f044c1b453e-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f044c1b453e-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 17054,
		&#039;title&#039; =&gt; &#039;IPAB dismisses Bayer&amp;#039;s stay plea in Nexavar case&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
-The Economic Times
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer&#039;s plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;We are yet to see the copy of the order, and cannot comment on the ruling,&amp;quot; said M Adinarayana, company secretary of Natco.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The German company was understandably disappointed. &amp;quot;We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients,&amp;quot; said a BayerBSE -0.15 % spokesperson.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research,&amp;quot; he added.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Justice Prabha Sridevan of IPAB rejected Bayer&#039;s petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, &amp;quot;it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life&amp;quot;.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy,&amp;quot; said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;In that sense, this order is a blow to the company on the legal front, if not on the monetary front,&amp;quot; he added.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month&#039;s therapy, and pay 6% royalty to Bayer on the total sales.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.&amp;nbsp;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 18 September, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/ipab-dismisses-bayers-stay-plea-in-nexavar-case/articleshow/1644217&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;ipab-dismisses-bayer039s-stay-plea-in-nexavar-case-17182&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 17182,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 17054,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | IPAB dismisses Bayer&amp;#039;s stay plea in Nexavar case&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,patents,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Economic Times





MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer&#039;s plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.





The Compulsory Licence (CL) issued...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;-The Economic Times&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer&#039;s plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;We are yet to see the copy of the order, and cannot comment on the ruling,&amp;quot; said M Adinarayana, company secretary of Natco.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The German company was understandably disappointed. &amp;quot;We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients,&amp;quot; said a BayerBSE -0.15 % spokesperson.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research,&amp;quot; he added.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Justice Prabha Sridevan of IPAB rejected Bayer&#039;s petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, &amp;quot;it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life&amp;quot;.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy,&amp;quot; said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;In that sense, this order is a blow to the company on the legal front, if not on the monetary front,&amp;quot; he added.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month&#039;s therapy, and pay 6% royalty to Bayer on the total sales.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.&amp;nbsp;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 17054,
	&#039;title&#039; =&gt; &#039;IPAB dismisses Bayer&amp;#039;s stay plea in Nexavar case&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
-The Economic Times
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer&#039;s plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;We are yet to see the copy of the order, and cannot comment on the ruling,&amp;quot; said M Adinarayana, company secretary of Natco.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The German company was understandably disappointed. &amp;quot;We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients,&amp;quot; said a BayerBSE -0.15 % spokesperson.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research,&amp;quot; he added.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Justice Prabha Sridevan of IPAB rejected Bayer&#039;s petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, &amp;quot;it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life&amp;quot;.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy,&amp;quot; said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;In that sense, this order is a blow to the company on the legal front, if not on the monetary front,&amp;quot; he added.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month&#039;s therapy, and pay 6% royalty to Bayer on the total sales.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.&amp;nbsp;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 18 September, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/ipab-dismisses-bayers-stay-plea-in-nexavar-case/articleshow/1644217&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;ipab-dismisses-bayer039s-stay-plea-in-nexavar-case-17182&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 17182,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 17054
$metaTitle = &#039;LATEST NEWS UPDATES | IPAB dismisses Bayer&amp;#039;s stay plea in Nexavar case&#039;
$metaKeywords = &#039;medicines,patents,Health&#039;
$metaDesc = &#039;
-The Economic Times





MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer&#039;s plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.





The Compulsory Licence (CL) issued...&#039;
$disp = &#039;&lt;div style=&quot;text-align: justify&quot;&gt;-The Economic Times&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer&#039;s plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;We are yet to see the copy of the order, and cannot comment on the ruling,&amp;quot; said M Adinarayana, company secretary of Natco.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The German company was understandably disappointed. &amp;quot;We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients,&amp;quot; said a BayerBSE -0.15 % spokesperson.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research,&amp;quot; he added.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Justice Prabha Sridevan of IPAB rejected Bayer&#039;s petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, &amp;quot;it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life&amp;quot;.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy,&amp;quot; said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;In that sense, this order is a blow to the company on the legal front, if not on the monetary front,&amp;quot; he added.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month&#039;s therapy, and pay 6% royalty to Bayer on the total sales.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.&amp;nbsp;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/ipab-dismisses-bayer039s-stay-plea-in-nexavar-case-17182.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | IPAB dismisses Bayer&#039;s stay plea in Nexavar case | Im4change.org</title>
    <meta name="description" content="
-The Economic Times





MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.





The Compulsory Licence (CL) issued..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>IPAB dismisses Bayer&#039;s stay plea in Nexavar case</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div style="text-align: justify">-The Economic Times</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>MUMBAI: </em>In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;We are yet to see the copy of the order, and cannot comment on the ruling,&quot; said M Adinarayana, company secretary of Natco.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The German company was understandably disappointed. &quot;We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients,&quot; said a BayerBSE -0.15 % spokesperson.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research,&quot; he added.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Justice Prabha Sridevan of IPAB rejected Bayer's petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, &quot;it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life&quot;.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy,&quot; said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;In that sense, this order is a blow to the company on the legal front, if not on the monetary front,&quot; he added.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month's therapy, and pay 6% royalty to Bayer on the total sales.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.&nbsp;</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f044c1b453e-trace').style.display = (document.getElementById('cakeErr67f044c1b453e-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f044c1b453e-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f044c1b453e-code').style.display = (document.getElementById('cakeErr67f044c1b453e-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f044c1b453e-context').style.display = (document.getElementById('cakeErr67f044c1b453e-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f044c1b453e-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f044c1b453e-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 17054,
		&#039;title&#039; =&gt; &#039;IPAB dismisses Bayer&amp;#039;s stay plea in Nexavar case&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
-The Economic Times
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer&#039;s plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;We are yet to see the copy of the order, and cannot comment on the ruling,&amp;quot; said M Adinarayana, company secretary of Natco.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The German company was understandably disappointed. &amp;quot;We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients,&amp;quot; said a BayerBSE -0.15 % spokesperson.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research,&amp;quot; he added.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Justice Prabha Sridevan of IPAB rejected Bayer&#039;s petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, &amp;quot;it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life&amp;quot;.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy,&amp;quot; said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;In that sense, this order is a blow to the company on the legal front, if not on the monetary front,&amp;quot; he added.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month&#039;s therapy, and pay 6% royalty to Bayer on the total sales.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.&amp;nbsp;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 18 September, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/ipab-dismisses-bayers-stay-plea-in-nexavar-case/articleshow/1644217&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;ipab-dismisses-bayer039s-stay-plea-in-nexavar-case-17182&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 17182,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 17054,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | IPAB dismisses Bayer&amp;#039;s stay plea in Nexavar case&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,patents,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Economic Times





MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer&#039;s plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.





The Compulsory Licence (CL) issued...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;-The Economic Times&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer&#039;s plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;We are yet to see the copy of the order, and cannot comment on the ruling,&amp;quot; said M Adinarayana, company secretary of Natco.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The German company was understandably disappointed. &amp;quot;We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients,&amp;quot; said a BayerBSE -0.15 % spokesperson.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research,&amp;quot; he added.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Justice Prabha Sridevan of IPAB rejected Bayer&#039;s petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, &amp;quot;it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life&amp;quot;.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy,&amp;quot; said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;In that sense, this order is a blow to the company on the legal front, if not on the monetary front,&amp;quot; he added.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month&#039;s therapy, and pay 6% royalty to Bayer on the total sales.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.&amp;nbsp;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 17054,
	&#039;title&#039; =&gt; &#039;IPAB dismisses Bayer&amp;#039;s stay plea in Nexavar case&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
-The Economic Times
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer&#039;s plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;We are yet to see the copy of the order, and cannot comment on the ruling,&amp;quot; said M Adinarayana, company secretary of Natco.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The German company was understandably disappointed. &amp;quot;We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients,&amp;quot; said a BayerBSE -0.15 % spokesperson.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research,&amp;quot; he added.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Justice Prabha Sridevan of IPAB rejected Bayer&#039;s petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, &amp;quot;it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life&amp;quot;.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy,&amp;quot; said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;In that sense, this order is a blow to the company on the legal front, if not on the monetary front,&amp;quot; he added.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month&#039;s therapy, and pay 6% royalty to Bayer on the total sales.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.&amp;nbsp;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 18 September, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/ipab-dismisses-bayers-stay-plea-in-nexavar-case/articleshow/1644217&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;ipab-dismisses-bayer039s-stay-plea-in-nexavar-case-17182&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 17182,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 17054
$metaTitle = &#039;LATEST NEWS UPDATES | IPAB dismisses Bayer&amp;#039;s stay plea in Nexavar case&#039;
$metaKeywords = &#039;medicines,patents,Health&#039;
$metaDesc = &#039;
-The Economic Times





MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer&#039;s plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.





The Compulsory Licence (CL) issued...&#039;
$disp = &#039;&lt;div style=&quot;text-align: justify&quot;&gt;-The Economic Times&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer&#039;s plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;We are yet to see the copy of the order, and cannot comment on the ruling,&amp;quot; said M Adinarayana, company secretary of Natco.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The German company was understandably disappointed. &amp;quot;We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients,&amp;quot; said a BayerBSE -0.15 % spokesperson.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research,&amp;quot; he added.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Justice Prabha Sridevan of IPAB rejected Bayer&#039;s petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, &amp;quot;it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life&amp;quot;.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy,&amp;quot; said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;In that sense, this order is a blow to the company on the legal front, if not on the monetary front,&amp;quot; he added.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month&#039;s therapy, and pay 6% royalty to Bayer on the total sales.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.&amp;nbsp;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/ipab-dismisses-bayer039s-stay-plea-in-nexavar-case-17182.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | IPAB dismisses Bayer&#039;s stay plea in Nexavar case | Im4change.org</title>
    <meta name="description" content="
-The Economic Times





MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.





The Compulsory Licence (CL) issued..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>IPAB dismisses Bayer&#039;s stay plea in Nexavar case</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div style="text-align: justify">-The Economic Times</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>MUMBAI: </em>In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;We are yet to see the copy of the order, and cannot comment on the ruling,&quot; said M Adinarayana, company secretary of Natco.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The German company was understandably disappointed. &quot;We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients,&quot; said a BayerBSE -0.15 % spokesperson.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research,&quot; he added.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Justice Prabha Sridevan of IPAB rejected Bayer's petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, &quot;it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life&quot;.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy,&quot; said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;In that sense, this order is a blow to the company on the legal front, if not on the monetary front,&quot; he added.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month's therapy, and pay 6% royalty to Bayer on the total sales.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.&nbsp;</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f044c1b453e-trace').style.display = (document.getElementById('cakeErr67f044c1b453e-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f044c1b453e-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f044c1b453e-code').style.display = (document.getElementById('cakeErr67f044c1b453e-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f044c1b453e-context').style.display = (document.getElementById('cakeErr67f044c1b453e-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f044c1b453e-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f044c1b453e-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 17054,
		&#039;title&#039; =&gt; &#039;IPAB dismisses Bayer&amp;#039;s stay plea in Nexavar case&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
-The Economic Times
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer&#039;s plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;We are yet to see the copy of the order, and cannot comment on the ruling,&amp;quot; said M Adinarayana, company secretary of Natco.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The German company was understandably disappointed. &amp;quot;We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients,&amp;quot; said a BayerBSE -0.15 % spokesperson.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research,&amp;quot; he added.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Justice Prabha Sridevan of IPAB rejected Bayer&#039;s petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, &amp;quot;it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life&amp;quot;.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy,&amp;quot; said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;In that sense, this order is a blow to the company on the legal front, if not on the monetary front,&amp;quot; he added.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month&#039;s therapy, and pay 6% royalty to Bayer on the total sales.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.&amp;nbsp;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 18 September, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/ipab-dismisses-bayers-stay-plea-in-nexavar-case/articleshow/1644217&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;ipab-dismisses-bayer039s-stay-plea-in-nexavar-case-17182&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 17182,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 17054,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | IPAB dismisses Bayer&amp;#039;s stay plea in Nexavar case&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,patents,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Economic Times





MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer&#039;s plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.





The Compulsory Licence (CL) issued...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;-The Economic Times&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer&#039;s plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;We are yet to see the copy of the order, and cannot comment on the ruling,&amp;quot; said M Adinarayana, company secretary of Natco.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The German company was understandably disappointed. &amp;quot;We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients,&amp;quot; said a BayerBSE -0.15 % spokesperson.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research,&amp;quot; he added.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Justice Prabha Sridevan of IPAB rejected Bayer&#039;s petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, &amp;quot;it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life&amp;quot;.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy,&amp;quot; said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;In that sense, this order is a blow to the company on the legal front, if not on the monetary front,&amp;quot; he added.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month&#039;s therapy, and pay 6% royalty to Bayer on the total sales.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.&amp;nbsp;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 17054,
	&#039;title&#039; =&gt; &#039;IPAB dismisses Bayer&amp;#039;s stay plea in Nexavar case&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div style=&quot;text-align: justify&quot;&gt;
-The Economic Times
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;em&gt;MUMBAI: &lt;/em&gt;In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer&#039;s plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;We are yet to see the copy of the order, and cannot comment on the ruling,&amp;quot; said M Adinarayana, company secretary of Natco.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
The German company was understandably disappointed. &amp;quot;We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients,&amp;quot; said a BayerBSE -0.15 % spokesperson.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research,&amp;quot; he added.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Justice Prabha Sridevan of IPAB rejected Bayer&#039;s petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, &amp;quot;it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life&amp;quot;.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy,&amp;quot; said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&amp;quot;In that sense, this order is a blow to the company on the legal front, if not on the monetary front,&amp;quot; he added.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month&#039;s therapy, and pay 6% royalty to Bayer on the total sales.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products.
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
&lt;br /&gt;
&lt;/div&gt;
&lt;div style=&quot;text-align: justify&quot;&gt;
Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.&amp;nbsp;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Economic Times, 18 September, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/ipab-dismisses-bayers-stay-plea-in-nexavar-case/articleshow/1644217&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;ipab-dismisses-bayer039s-stay-plea-in-nexavar-case-17182&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 17182,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 17054
$metaTitle = &#039;LATEST NEWS UPDATES | IPAB dismisses Bayer&amp;#039;s stay plea in Nexavar case&#039;
$metaKeywords = &#039;medicines,patents,Health&#039;
$metaDesc = &#039;
-The Economic Times





MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer&#039;s plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.





The Compulsory Licence (CL) issued...&#039;
$disp = &#039;&lt;div style=&quot;text-align: justify&quot;&gt;-The Economic Times&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;em&gt;MUMBAI: &lt;/em&gt;In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer&#039;s plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;We are yet to see the copy of the order, and cannot comment on the ruling,&amp;quot; said M Adinarayana, company secretary of Natco.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;The German company was understandably disappointed. &amp;quot;We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients,&amp;quot; said a BayerBSE -0.15 % spokesperson.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research,&amp;quot; he added.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Justice Prabha Sridevan of IPAB rejected Bayer&#039;s petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, &amp;quot;it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life&amp;quot;.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy,&amp;quot; said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&amp;quot;In that sense, this order is a blow to the company on the legal front, if not on the monetary front,&amp;quot; he added.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month&#039;s therapy, and pay 6% royalty to Bayer on the total sales.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products.&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;&lt;br /&gt;&lt;/div&gt;&lt;div style=&quot;text-align: justify&quot;&gt;Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.&amp;nbsp;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/ipab-dismisses-bayer039s-stay-plea-in-nexavar-case-17182.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | IPAB dismisses Bayer&#039;s stay plea in Nexavar case | Im4change.org</title>
    <meta name="description" content="
-The Economic Times





MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.





The Compulsory Licence (CL) issued..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>IPAB dismisses Bayer&#039;s stay plea in Nexavar case</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div style="text-align: justify">-The Economic Times</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>MUMBAI: </em>In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;We are yet to see the copy of the order, and cannot comment on the ruling,&quot; said M Adinarayana, company secretary of Natco.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The German company was understandably disappointed. &quot;We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients,&quot; said a BayerBSE -0.15 % spokesperson.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research,&quot; he added.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Justice Prabha Sridevan of IPAB rejected Bayer's petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, &quot;it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life&quot;.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy,&quot; said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;In that sense, this order is a blow to the company on the legal front, if not on the monetary front,&quot; he added.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month's therapy, and pay 6% royalty to Bayer on the total sales.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.&nbsp;</div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 17054,
		'title' => 'IPAB dismisses Bayer's stay plea in Nexavar case',
		'subheading' => '',
		'description' => '<div style="text-align: justify">
-The Economic Times
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
<em>MUMBAI: </em>In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
&quot;We are yet to see the copy of the order, and cannot comment on the ruling,&quot; said M Adinarayana, company secretary of Natco.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The German company was understandably disappointed. &quot;We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients,&quot; said a BayerBSE -0.15 % spokesperson.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
&quot;The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research,&quot; he added.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Justice Prabha Sridevan of IPAB rejected Bayer's petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, &quot;it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life&quot;.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
&quot;The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy,&quot; said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
&quot;In that sense, this order is a blow to the company on the legal front, if not on the monetary front,&quot; he added.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month's therapy, and pay 6% royalty to Bayer on the total sales.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.&nbsp;
</div>',
		'credit_writer' => 'The Economic Times, 18 September, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/ipab-dismisses-bayers-stay-plea-in-nexavar-case/articleshow/1644217',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'ipab-dismisses-bayer039s-stay-plea-in-nexavar-case-17182',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 17182,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 17054,
	'metaTitle' => 'LATEST NEWS UPDATES | IPAB dismisses Bayer&#039;s stay plea in Nexavar case',
	'metaKeywords' => 'medicines,patents,Health',
	'metaDesc' => '
-The Economic Times





MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.





The Compulsory Licence (CL) issued...',
	'disp' => '<div style="text-align: justify">-The Economic Times</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>MUMBAI: </em>In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;We are yet to see the copy of the order, and cannot comment on the ruling,&quot; said M Adinarayana, company secretary of Natco.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The German company was understandably disappointed. &quot;We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients,&quot; said a BayerBSE -0.15 % spokesperson.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research,&quot; he added.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Justice Prabha Sridevan of IPAB rejected Bayer's petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, &quot;it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life&quot;.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy,&quot; said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;In that sense, this order is a blow to the company on the legal front, if not on the monetary front,&quot; he added.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month's therapy, and pay 6% royalty to Bayer on the total sales.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.&nbsp;</div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 17054,
	'title' => 'IPAB dismisses Bayer&#039;s stay plea in Nexavar case',
	'subheading' => '',
	'description' => '<div style="text-align: justify">
-The Economic Times
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
<em>MUMBAI: </em>In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
&quot;We are yet to see the copy of the order, and cannot comment on the ruling,&quot; said M Adinarayana, company secretary of Natco.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
The German company was understandably disappointed. &quot;We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients,&quot; said a BayerBSE -0.15 % spokesperson.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
&quot;The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research,&quot; he added.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Justice Prabha Sridevan of IPAB rejected Bayer's petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, &quot;it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life&quot;.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
&quot;The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy,&quot; said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
&quot;In that sense, this order is a blow to the company on the legal front, if not on the monetary front,&quot; he added.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month's therapy, and pay 6% royalty to Bayer on the total sales.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products.
</div>
<div style="text-align: justify">
<br />
</div>
<div style="text-align: justify">
Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.&nbsp;
</div>',
	'credit_writer' => 'The Economic Times, 18 September, 2012, http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/ipab-dismisses-bayers-stay-plea-in-nexavar-case/articleshow/1644217',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'ipab-dismisses-bayer039s-stay-plea-in-nexavar-case-17182',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 17182,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 17054
$metaTitle = 'LATEST NEWS UPDATES | IPAB dismisses Bayer&#039;s stay plea in Nexavar case'
$metaKeywords = 'medicines,patents,Health'
$metaDesc = '
-The Economic Times





MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.





The Compulsory Licence (CL) issued...'
$disp = '<div style="text-align: justify">-The Economic Times</div><div style="text-align: justify"><br /></div><div style="text-align: justify"><em>MUMBAI: </em>In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;We are yet to see the copy of the order, and cannot comment on the ruling,&quot; said M Adinarayana, company secretary of Natco.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">The German company was understandably disappointed. &quot;We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients,&quot; said a BayerBSE -0.15 % spokesperson.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research,&quot; he added.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Justice Prabha Sridevan of IPAB rejected Bayer's petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, &quot;it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life&quot;.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy,&quot; said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">&quot;In that sense, this order is a blow to the company on the legal front, if not on the monetary front,&quot; he added.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month's therapy, and pay 6% royalty to Bayer on the total sales.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products.</div><div style="text-align: justify"><br /></div><div style="text-align: justify">Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.&nbsp;</div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

IPAB dismisses Bayer's stay plea in Nexavar case

-The Economic Times MUMBAI: In a victory to generic drugmakers, the Intellectual Property Appellate Board (IPAB) of Chennai has dismissed German pharma major Bayer's plea, seeking a stay on the Compulsory Licence issued to Hyderabad-based drugmaker Natco. The Compulsory Licence (CL) issued by the Controller of Patents in March this year allowed Natco to make and sell a generic version of Nexavar - used for treating liver and kidney cancer - at less than 3% of the cost charged by the German company. "We are yet to see the copy of the order, and cannot comment on the ruling," said M Adinarayana, company secretary of Natco. The German company was understandably disappointed. "We are disappointed with the decision to reject the stay petition. We will rigorously continue to defend our intellectual property rights which are a prerequisite for bringing innovative medicines to patients," said a BayerBSE -0.15 % spokesperson. "The order of the Patent Controller of India (the office that issued the licence) damages the international patent system and endangers pharmaceutical research," he added. Bayer is now going to focus on the more contentious issue of whether the CL granted by the patent office of Mumbai is valid or not, and the case may drag on for a while. Justice Prabha Sridevan of IPAB rejected Bayer's petition on the grounds that the company did not make prime facie case for the grant of stay. It also said that if the stay is granted, "it will definitely jeopardise the interest of the public who need the drug at the later stage of the disease, since Bayer has admitted that this drug improves the quality of life". "The product is an important cancer drug and getting a stay was important for Bayer because it would have given them some time to think about their future strategy," said Aliasgar Dholkawala, a specialist in patents and trademark in law firm Wadia Ghandy and Co. "In that sense, this order is a blow to the company on the legal front, if not on the monetary front," he added. Compulsory Licence is a patent system under the World Trade Organisation (WTO) where a government allows a company to manufacture a patented drug without the consent of the innovator company. In March this year, India granted its first-ever CL, allowing Natco to sell a generic version of the cancer drug at 8,800 for a month's therapy, and pay 6% royalty to Bayer on the total sales. India is in the middle of raging patent battle, where domestic drugmakers are locked in a bitter legal battle with multinationals over their patented products. Last week, the Delhi High Court ruled in favour of Cipla regarding a patent infringement suit filed Swiss drugmaker Roche over its cancer drug Tarceva, while another Swiss drugmaker Novartis is awaiting an important ruling from the Supreme Court over its cancer drug Glivec.